Standard BioTools Inc. filings document the regulatory record for a life-science research tools company centered on mass cytometry, microfluidics, genomics, single-cell proteomics and spatial proteomics. Current reports cover operating results, revenue outlook disclosures, restructuring and cost-savings actions, capital-structure changes, material agreements and risk factors tied to its research-use instrument, consumable and service portfolio.
Proxy materials describe board elections, executive compensation votes, auditor ratification, equity incentive plan approvals and employee stock purchase plan amendments. Form 8-K filings also record material events such as the completed SomaLogic sale, related financial disclosures, shareholder voting matters and Nasdaq continued-listing compliance notices.
Cox Troy reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Troy Cox reported an award of 57,264 restricted stock units representing common stock on February 26, 2026. These RSUs were valued at $1.17 per share for reporting purposes and bring his directly held stake to 376,586 shares after the grant.
The RSUs vest in four equal 25% installments on the last day of the last month of each fiscal quarter of 2026, conditioned on his continued board service through each vesting date. Cox elected to receive this equity grant instead of $67,000 in cash compensation for his board role.
Carey Thomas D. reported acquisition or exercise transactions in this Form 4 filing.
STANDARD BIOTOOLS INC. director Thomas D. Carey received a grant of 51,282 shares of common stock in the form of restricted stock units valued at $1.17 per share. These RSUs were taken in lieu of $60,000 in cash board compensation and will vest in four equal quarterly installments during 2026, subject to his continued service. Following this grant, his directly held common stock totals 245,340 shares.
STANDARD BIOTOOLS INC. President & CEO Michael Egholm reported a Form 4 showing a tax-related share disposition. On the transaction date, 66,127 shares of common stock were withheld at $1.15 per share to cover tax withholding obligations from vesting restricted stock units. After this tax-withholding disposition, Egholm directly owned 5,551,710 shares of common stock.
STANDARD BIOTOOLS INC. executive Sean Mackay, SVP & Chief Business Officer, reported a tax-related share disposition. On February 23, 2026, 19,661 shares of common stock were withheld at $1.15 per share to cover tax obligations from previously granted restricted stock units that vested. After this withholding, Mackay directly holds 760,174 shares of Standard BioTools common stock. This was a tax-withholding disposition, not an open-market purchase or sale.
STANDARD BIOTOOLS INC. Chief Financial Officer Hanjoon Alex Kim reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 12,740 shares of common stock at $1.15 per share to cover tax obligations. After this withholding, Kim directly owns 2,407,346 common shares, which includes 5,000 shares acquired on November 28, 2025 under the employee stock purchase plan.
Standard BioTools Inc. reported fourth-quarter 2025 revenue from continuing operations of $23.8 million and full-year 2025 revenue of $85.3 million, both down modestly year over year. Despite lower sales, gross margin improved to 47.8% for the quarter and 49.9% for the year, helped by mix and efficiency gains.
Operating expenses fell 11% in 2025 to $152.8 million as the company fully operationalized over $40 million of annualized cost savings. Net loss from continuing operations narrowed to $58.8 million, aided by a $38.4 million non-cash tax valuation allowance release. Cash, cash equivalents and liquid investments were $210.7 million at year-end, and management cited approximately $550 million in cash and investments after the January 30, 2026 SomaLogic transaction. For 2026, the company guides revenue to $80–$85 million, with seasonality similar to prior years.
Standard BioTools Inc. filed an amended report to add unaudited pro forma financial statements reflecting the completed sale of its SomaScan business (SomaLogic and Sengenics entities) to Illumina. The company received approximately $363.7 million in net cash proceeds at closing and recognized a pro forma gain on sale of about $161.9 million, strengthening its cash position. It also became eligible for up to $75 million in additional earnout payments tied to SomaScan-related revenues in fiscal 2025 and 2026, plus a 2% royalty on SOMAmer-based NGS library prep kit revenues for 10 years and a co-exclusive IP license for certain Single SOMAmer assays. Pro forma 2024 results remove the disposed operations, reducing reported revenue but narrowing net loss attributable to common stockholders from $184.9 million to $133.8 million.
Standard BioTools has completed the previously announced sale of all equity interests in SomaLogic, Inc. and related Sengenics entities to Illumina, divesting its aptamer-based and functional proteomics business. Illumina agreed to pay up to $425 million in cash, including an upfront $350 million at closing and up to $75 million in earnout payments tied to specified revenue targets for SOMAmer-based products in fiscal years 2025 and 2026.
The company is retaining its mass cytometry and microfluidics businesses. As additional consideration, Standard BioTools will receive specified royalty streams on net revenues from SOMAmer-based next-generation sequencing library preparation kits and from Single SOMAmers, and it obtained a license to Single SOMAmer intellectual property for potential singleplex affinity assays. A transition services agreement will support Illumina’s operation of the divested business. Following the transaction, Standard BioTools and its subsidiaries will no longer receive payments under SomaLogic’s collaboration agreement with Illumina Cambridge.
Standard BioTools Inc. filed a Form 8-K to furnish a press release containing certain preliminary, unaudited financial results for the three months and fiscal year ended December 31, 2025. These figures are based on current expectations and may be adjusted after completion of the company’s year-end audit, financial closing procedures, and internal reviews.
The press release is included as Exhibit 99.1. The company notes that this information, including the exhibit, is being furnished rather than filed under the Securities Exchange Act, which limits its use for certain legal purposes.
Standard BioTools Inc. received a Schedule 13G filing showing that investment entities affiliated with MAK Capital have become significant shareholders. MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman together report beneficial ownership of 19,967,565 shares of Standard BioTools common stock, representing 5.19% of the outstanding shares. The percentage is based on 384,565,414 shares outstanding as of November 2, 2025, and MAK’s position as of January 7, 2026. The reporting parties state that the securities were not acquired and are not held for the purpose of changing or influencing control of the company, and they hold shared voting and dispositive power over all reported shares.